<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mendelian susceptibility to mycobacterial diseases: Specific defects</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mendelian susceptibility to mycobacterial diseases: Specific defects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mendelian susceptibility to mycobacterial diseases: Specific defects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alexandra F Freeman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven M Holland, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer M Puck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H6698822"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The conditions grouped together under Mendelian susceptibility to mycobacterial diseases (MSMD; MIM #209950) are caused by genetic defects affecting the interactions of mononuclear phagocytes and T helper cells around the synthesis and response to interferon (IFN) gamma and interleukin (IL) 12, often referred to as the type 1 T helper cell (Th1) pathway [<a href="#rid1">1</a>]. These defects were predominantly identified through Bacille Calmette-Guérin (BCG) susceptibility but are unified by problems with the control and killing of intracellular pathogens such as mycobacteria and also include bacteria (eg, <em>Salmonella</em>, <em>Burkholderia</em>), fungi (eg, <em>Histoplasma</em>, <em>Talaromyces</em>), and viruses (eg, herpes simplex virus [HSV], varicella-zoster virus [VZV])  (<a class="graphic graphic_table graphicRef129034" href="/d/graphic/129034.html" rel="external">table 1</a>).</p><p>In countries in which BCG is not given, the clinical and infectious manifestations of MSMD may be unrelated to mycobacteria.</p><p>This topic reviews specific genetic defects that are considered forms of MSMD  (<a class="graphic graphic_table graphicRef140002" href="/d/graphic/140002.html" rel="external">table 2</a>). An overview topic reviews pathogenesis, typical presentation, and general approach to diagnosis and management. (See  <a class="medical medical_review" href="/d/html/89801.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: An overview"</a>.)</p><p class="headingAnchor" id="H1040482217"><span class="h1">IL12RB1 DEFICIENCY</span><span class="headingEndMark"> — </span>The functional interleukin (IL) 12 receptor requires both IL-12 receptor beta 1 (IL12RB1) and IL-12 receptor beta 2 (IL12RB2) chains. Absence of either chain leads to complete deficiency of IL-12 signaling. IL12RB1 is slightly promiscuous; it complexes with IL12RB2 for IL-12 signaling or with IL-23R for IL-23 signaling. Pathogenic variants in <em>IL12RB1</em>, encoded on chromosome 19p13.1, have been identified in patients with disseminated infections, including <em>Salmonella,</em> nontuberculous mycobacteria (NTM), tuberculosis, and Bacillus Calmette-Guérin (BCG) following vaccination [<a href="#rid2">2-10</a>]. Penetrance and expressivity in IL12RB1 deficiency (MIM #614891) are highly variable, with some affected patients asymptomatic, whereas others develop severe disseminated BCG or NTM early in life. Variably formed granulomas are typically present in histopathology and frequently have high numbers of organisms. Despite the variable penetrance, mortality is approximately 30 percent.</p><p>All reported patients with IL12RB1 deficiency have biallelic missense or nonsense pathogenic variants in the extracellular domain of the IL12RB1 that usually preclude the surface expression of the IL12RB1 protein [<a href="#rid11">11</a>]. Interferon (IFN) gamma secretion by otherwise healthy T cells and natural killer (NK) cells is impaired as a result of defective IL-12R signaling. Ex vivo studies typically show no IL12RB1 on T lymphoblasts and defective intracellular signal transducer and activator of transcription (STAT) 4 phosphorylation and IFN-gamma secretion in response to IL-12 stimulation [<a href="#rid11">11,12</a>]. Carriers are clinically healthy with normal IL-12 signaling and IFN-gamma production patterns.</p><p>In an international study of 141 patients, the first serious disseminated infection occurred on average at 2.4 years in the 102 probands and was caused by BCG (64 percent), nontyphoidal <em>Salmonella</em> (22 percent), NTM (9 percent), or <em>M. tuberculosis</em> (4 percent) [<a href="#rid11">11</a>]. Mild chronic mucocutaneous candidiasis (CMCC) was reported in 23 percent of all patients, possibly reflecting impaired IL-23-dependent IL-17 production, whereas invasive candidiasis was uncommon [<a href="#rid13">13</a>]. BCG disease was inversely associated with subsequent infection with NTM. Twenty-seven percent of genetically affected siblings were asymptomatic. However, the overall mortality rate was approximately 30 percent, with a mean age at last follow-up visit of 12.7 years (range 0.5 to 46.4 years). Patients with NTM infection had the worst prognosis.</p><p>IFN-gamma therapy, initiated at the standard doses used in chronic granulomatous disease (CGD), may provide benefit in patients for whom antimycobacterials alone have been incompletely successful. The dose can be escalated based upon the patient's tolerance and response, with monitoring for an overexuberant inflammatory reaction. There is limited hematopoietic cell transplantation (HCT) experience, and so its role remains undefined, but it has been successful in rare refractory cases. (See  <a class="medical medical_review" href="/d/html/3923.html" rel="external">"Chronic granulomatous disease: Treatment and prognosis", section on 'Immunomodulatory therapy with interferon-gamma'</a> and <a class="local">'Autosomal dominant partial IFNGR1 deficiency'</a> below.)</p><p class="headingAnchor" id="H2378582030"><span class="h1">IL12RB2 AND IL-23 RECEPTOR DEFICIENCIES</span><span class="headingEndMark"> — </span>There are rare reports of homozygous defects in both interleukin 12 receptor beta 2 (IL12RB2) and IL-23 receptor (IL-23R) causing variable susceptibility to Bacillus Calmette-Guérin (BCG), nontuberculous mycobacteria (NTM), and tuberculosis. In the two reported families with these defects, chronic mucocutaneous candidiasis (CMCC) was not seen compared with the CMCC susceptibly seen with IL12RB1 deficiency [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3"><span class="h1">IFN-GAMMA RECEPTOR DEFICIENCIES</span></p><p class="headingAnchor" id="H922762090"><span class="h2">Role of IFN-gamma</span><span class="headingEndMark"> — </span>Interferon (IFN) gamma is the type II IFN produced primarily by T and natural killer (NK) cells, while type I IFNs (eg, IFN-alpha, IFN-beta, IFN-omega) are produced by epithelial cells, dendritic cells, T cells, monocytes/macrophages, and neurons, among others. IFN-gamma is critical to both innate and adaptive immunity, functioning as the primary activator of macrophages in addition to NK cells and neutrophils, and for the control of many intracellular pathogens.</p><p class="headingAnchor" id="H1372730829"><span class="h2">Types of defects</span><span class="headingEndMark"> — </span>The functional IFN-gamma receptor (IFNGR) requires both the IFNGR1 and IFNGR2 chains. The absence of either chain leads to complete receptor failure. Pathogenic variants in both IFNGR chains have been identified and characterized [<a href="#rid15">15-22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>IFN-gamma receptor 1 deficiency (<em>IFNGR1</em>, gene encoded on chromosome 6q23-q24)</p><p class="bulletIndent1"><span class="glyph">●</span>IFN-gamma receptor 2 deficiency (<em>IFNGR2</em>, gene encoded on chromosome 21q22.1-q22.2)</p><p></p><p>Autosomal recessive (AR) defects in <em>IFNGR1</em> and <em>IFNGR2</em> result in complete or partial deficiencies. Autosomal dominant (AD) inheritance resulting in partial deficiencies is also observed for both genes [<a href="#rid1">1,23</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Autosomal recessive complete IFNGR1 or IFNGR2 deficiencies</span><span class="headingEndMark"> — </span>Patients with AR complete IFNGR1 (MIM #209950) or IFNGR2 (MIM #614889) deficiency tend to develop severe disseminated mycobacterial disease in infancy or early childhood, requiring long-term antimycobacterial therapy. By contrast, AD mutations retain residual signaling and are generally milder. In one large series, affected patients with biallelic AR <em>IFNGR1</em> pathogenic variants had more frequent mycobacterial disease episodes (mean of 19 per 100 person-years), more disseminated disease (mean of four organs per infection), and shorter mean disease-free intervals (mean 1.6 years) compared with patients with AD disease [<a href="#rid24">24</a>]. Although infection with mycobacteria and <em>Salmonella </em>are predominantly associated with these genetic defects [<a href="#rid24">24</a>], the phenotype also includes increased susceptibility to cytomegalovirus (CMV), varicella-zoster virus, <em>Listeria monocytogenes</em>,<em> </em>and respiratory viruses such as respiratory syncytial virus (RSV) and parainfluenza virus [<a href="#rid20">20,25,26</a>]. The typical histopathologic feature in areas of infections is failure to form well-circumscribed tuberculoid granulomas [<a href="#rid24">24</a>].</p><p>AR pathogenic variants in <em>IFNGR1</em> or <em>IFNGR2</em> that lead to complete loss of protein expression map to the extracellular domains of the receptor proteins [<a href="#rid16">16,21</a>]. Flow cytometric analyses of peripheral blood mononuclear cells (PBMCs) show significantly decreased or absent cell surface expression of IFNGR1 or IFNGR2. Thus, signaling via the IFNGR is defective, which is detected as absent intracellular staining for phosphorylated signal transducer and activator of transcription (STAT) 1 protein [<a href="#rid27">27</a>] after IFN-gamma stimulation. Detection of pathogenic variants at the molecular level confirms the diagnosis. (See  <a class="medical medical_review" href="/d/html/3937.html" rel="external">"Flow cytometry for the diagnosis of inborn errors of immunity"</a>.)</p><p>Patients with this defect typically require aggressive treatment with antimycobacterial antibiotics for disseminated mycobacterial disease followed by transplantation. (See  <a class="medical medical_review" href="/d/html/14425.html" rel="external">"Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children", section on 'Antimycobacterial therapy'</a>.)</p><p>IFN-gamma cytokine replacement therapy has no value in patients with AR complete defects of IFNGR1 and IFNGR2 since a functional IFNGR is absent. Adjuvant IFN-alpha along with antimycobacterial antibiotics has been used to treat disseminated <em>Mycobacterium avium</em> complex (MAC) in patients with complete IFNGR1 defects, with the goal of turning on shared downstream transcription factors, such as STAT1, through the IFN-alpha receptor [<a href="#rid28">28</a>].</p><p>Early mortality occurs without hematopoietic cell transplantation (HCT) in patients with complete IFNGR defects. The success of HCT is mostly related to the patient's overall status, and efforts should be taken to control mycobacterial infection before transplantation. However, patients have been successfully transplanted despite active mycobacterial infection [<a href="#rid29">29</a>]. There was high mortality and graft failure with early attempts at HCT for IFNGR deficiency, especially in those with poor control of disseminated infection. Most transplants have been performed with myeloablative regimens. In a report from 2004, of eight patients who received 11 HCTs, four died, and two had poor engraftment; the two who had full remission had received T cell-replete grafts from matched siblings following full ablation [<a href="#rid30">30</a>]. Other patients were successfully transplanted after myeloablative conditioning from matched unrelated or related donors [<a href="#rid31">31,32</a>]. Another survey reported on 30 transplants in 28 patients, of whom 23 were alive (82 percent overall survival) at a mean of 2.5 years posttransplant [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Autosomal dominant partial IFNGR1 deficiency</span><span class="headingEndMark"> — </span>AD partial IFNGR1 deficiency (MIM #615978) is more common than AR complete IFNGR deficiency. The clinical presentation is usually later in childhood or in adolescence with more localized infection. Patients with AD IFNGR1 may present with localized or disseminated Bacillus Calmette-Guérin (BCG) or nontuberculous mycobacterial (NTM) infections [<a href="#rid34">34</a>], histoplasmosis [<a href="#rid35">35</a>], coccidioidomycosis [<a href="#rid36">36</a>], or salmonellosis [<a href="#rid24">24</a>]. Most patients with AD IFNGR deficiency develop NTM osteomyelitis, a manifestation that is the hallmark for this genotype in North America and Europe [<a href="#rid24">24</a>]. Histology shows mature-looking paucibacillary granulomas  (<a class="graphic graphic_picture graphicRef132768" href="/d/graphic/132768.html" rel="external">picture 1</a>), which are occasionally mistaken for malignancy [<a href="#rid37">37</a>]. (See <a class="local">'Autosomal recessive partial IFNGR1 or IFNGR2 deficiencies'</a> below.)</p><p>AD partial IFNGR1 deficiency is most often due to small frameshift deletions in a deletion hotspot just inside the intracellular domain of the <em>IFNGR1</em> gene, leading to truncation of most of the intracellular domain [<a href="#rid38">38</a>]. Mutant chains with intact extracellular domains can still bind IFN-gamma but fail to transduce the signal because the Janus kinase (JAK) and STAT1 binding motifs are missing. In addition, the mutant chains do not get recycled off of the plasma membrane, because the receptor-recycling domain is deleted [<a href="#rid39">39</a>]. These abundant mutant receptors compete with wild-type receptors at the cell surface for binding IFN-gamma, but they do not block all signaling, which is why this is a dominant negative (DN) partial defect with retained granuloma formation and localized disease.</p><p>Flow cytometric analysis of monocytes from affected patients demonstrates a three- to fivefold increase in cell surface IFNGR1 protein expression compared with healthy control monocytes. However, STAT1 phosphorylation following in vitro stimulation with IFN-gamma is reduced even at 100-fold higher concentrations of IFN-gamma. Diagnosis is confirmed by identification of a pathogenic variant by deoxyribonucleic acid (DNA) sequencing. (See  <a class="medical medical_review" href="/d/html/3937.html" rel="external">"Flow cytometry for the diagnosis of inborn errors of immunity"</a>.)</p><p>Patients with AD partial IFNGR1 deficiency have a much more favorable response to antimycobacterial treatment [<a href="#rid40">40,41</a>] and adjunctive IFN-gamma therapy than do patients with AR complete IFNGR1 deficiency, although they sometimes require a relatively high dose of IFN-gamma [<a href="#rid18">18</a>]. Combination antibiotics should be used based upon the <em>Mycobacterium</em> isolated. IFN-gamma is initially dosed at 50 mcg/m<sup>2</sup> (or 1 million international units/m<sup>2</sup>) for patients whose <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.rxlist.com%2Fbody_surface_area%2Fdefinition.htm&amp;token=Sr1kTXVwaOOZxS8kSo2DMT18sTPclXC5CTVhw1laQaoZgteFEFZ7EIAvhKOjBBFSeFMlJeSn9L2uO%2FBvtERt4w%3D%3D&amp;TOPIC_ID=3958" target="_blank">body surface area</a> is &gt;0.5 m<sup>2</sup> and 1.5 mcg/kg/dose for patients whose body surface area is ≤0.5 m<sup>2</sup>, which is the standard dosing for chronic granulomatous disease (CGD). The dose can then be escalated gradually based upon patient tolerance and response. After completion of treatment with combination antibiotics, if a mycobacterial infection is found, secondary prophylaxis is typically given with a macrolide such as <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> dosed at 250 mg daily for adults or 5 mg/kg/day for children (maximum dose 250 mg daily). Some severe cases have undergone successful transplantation [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/14425.html" rel="external">"Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children", section on 'Antimycobacterial therapy'</a> and  <a class="medical medical_review" href="/d/html/3923.html" rel="external">"Chronic granulomatous disease: Treatment and prognosis", section on 'Immunomodulatory therapy with interferon-gamma'</a>.)</p><p class="headingAnchor" id="H302431363"><span class="h2">Autosomal dominant partial IFNGR2 deficiency</span><span class="headingEndMark"> — </span>AD partial IFNGR2 deficiency has been described in several families [<a href="#rid43">43,44</a>]. The DN pathogenic variant is hypofunctional. IFNGR activity was low in mildly symptomatic or asymptomatic heterozygous family members and absent when in homozygosity. One homozygous patient had NTM osteomyelitis, and the other had disseminated CMV and <em>M. avium</em> infection.</p><p class="headingAnchor" id="H6"><span class="h2">Autosomal recessive partial IFNGR1 or IFNGR2 deficiencies</span><span class="headingEndMark"> — </span>Rare AR partial defects in both IFNGR1 and IFNGR2, in which IFN-gamma signal transduction is impaired but not abolished, have also been identified [<a href="#rid21">21,45-47</a>]. The clinical phenotype may be milder than that of patients with complete defects. Patients may present later in life with more limited disease. Affected patients can have normal granuloma formation.</p><p>AR partial IFNGR defects are often due to homozygous recessive missense pathogenic variants causing amino acid replacements in the extracellular domains or compound heterozygous pathogenic variants allowing a hypomorphic cellular phenotype with some IFN-gamma signaling [<a href="#rid28">28</a>]. Overall, the receptor is expressed on the cell surface, and the response to IFN-gamma is diminished, but not totally abolished, at the cellular level.</p><p>Diagnosis is established by detection of the pathogenic variants by DNA sequencing. Flow cytometric evaluation of the receptor may be normal since the dysfunctional receptor may still be expressed on the cell surface at normal amounts. However, IFN-gamma signaling is diminished. (See  <a class="medical medical_review" href="/d/html/3937.html" rel="external">"Flow cytometry for the diagnosis of inborn errors of immunity"</a>.)</p><p>Disseminated infection may occur but is often responsive to antimycobacterial drugs (and adjunctive IFN-gamma, if needed), unlike in patients with AR complete IFNGR defects [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H8"><span class="h1">IL-12 p40 DEFICIENCY</span><span class="headingEndMark"> — </span>IL-12p40 complexes with IL-12p35 to make IL-12p70, the cytokine referred to as interleukin (IL) 12. IL-12p40 can also complex with IL-23p19 to form the cytokine IL-23. Patients with loss-of-function (LOF) autosomal recessive (AR) pathogenic variants in the gene encoding IL-12p40 (<em>IL12B</em>; encoded on chromosome 5q31.1-33.1) have a clinical phenotype similar to IL-12 receptor beta 1 (IL12RB1) deficiency [<a href="#rid48">48-50</a>]. Neither the IL-12p40 subunit nor the IL-12p70 heterodimer are detectable by enzyme-linked immunosorbent assay (ELISA) in these patients. Residual, IL-12 independent interferon (IFN) gamma secretion pathways persist, as reflected by the capacity to form organized granulomata.</p><p>Most patients present in early childhood (mean age one year), typically with disseminated or regional Bacillus Calmette-Guérin (BCG) disease. Disseminated and recurrent <em>Salmonella</em> infections are common. Visceral leishmaniasis has also been described [<a href="#rid51">51</a>]. The mortality rate in the largest series was 32 percent in symptomatic patients, with a mean age at death of seven years [<a href="#rid50">50</a>]. Similar to those with IL12RB1 deficiency, the penetrance is variable, and some persons with biallelic pathogenic variants are asymptomatic.</p><p>Treatments of choice are antibiotics and subcutaneous IFN-gamma, as described above for IL12RB1 deficiency. However, mortality remains high. (See <a class="local">'Autosomal dominant partial IFNGR1 deficiency'</a> above.)</p><p class="headingAnchor" id="H9"><span class="h1">STAT1 DEFECTS</span></p><p class="headingAnchor" id="H3176052010"><span class="h2">Role of STAT1</span><span class="headingEndMark"> — </span>Signal transducer and activator of transcription (STAT) 1 (encoded on chromosome 2q32.2-q32.3) is a critical signal transducer for both the interferon (IFN) gamma receptor and IFN-alpha/beta receptors and is required for responses to IFN-gamma, alpha, and beta [<a href="#rid2">2</a>]. Following IFN-gamma stimulation, STAT1 becomes phosphorylated and homodimerizes to form the gamma-activating factor (GAF). In contrast, following IFN-alpha/beta stimulation, phosphorylated STAT1 combines with both STAT2 and p48, a cytoplasmic protein, to form heterotrimers known as IFN-stimulated gene factor 3 (ISGF3).</p><p class="headingAnchor" id="H133145424"><span class="h2">Types of defects</span><span class="headingEndMark"> — </span>STAT1<em> </em>defects vary in severity and clinical presentation, depending upon the pathogenic variant and its effect on protein expression and function. The types of pathogenic variants include amorphic (no function), hypomorphic (reduced function), and hypermorphic (increased function). Biallelic recessive amorphic loss-of-function (LOF) variants lead to partial or complete deficiency of STAT1. Heterozygous dominant negative (DN) variants in STAT1 lead to impaired, but not fully abolished, responses to IFN-gamma. Finally, heterozygous hypermorphic-activating pathogenic variants in STAT1 confer dominant gains of function (GOF). The presentation of these different forms of STAT1 defects can range from isolated thrush, to disseminated infections, to severe immunodeficiency that is lethal in the first year of life.</p><p class="headingAnchor" id="H12958669"><span class="h2">Autosomal recessive complete STAT1 deficiency</span><span class="headingEndMark"> — </span>Autosomal recessive (AR) complete STAT1 deficiency (MIM #613796) caused by biallelic amorphic <em>STAT1</em> alleles is a rare, severe immunodeficiency that leads to increased susceptibility to mycobacterial and viral infections. Patients die in infancy in the absence of hematopoietic cell transplantation (HCT). A complete loss of wild-type protein underlies the observed biologic defect in this form of STAT1 deficiency [<a href="#rid52">52,53</a>]. Survival has been poor due to disseminated Bacillus Calmette-Guérin (BCG) and severe viral infections including herpes viruses. Early HCT prior to infection may improve outcomes in patients with AR complete STAT1 deficiency.</p><p class="headingAnchor" id="H3728548992"><span class="h2">Autosomal recessive partial STAT1 deficiency</span><span class="headingEndMark"> — </span>AR loss-of-function (LOF) STAT1 deficiency is caused by hypomorphic missense pathogenic variants that lead to impaired STAT1 expression (LOF) [<a href="#rid54">54,55</a>]. GAF-mediated immunity is more impaired than ISGF3-mediated immunity. Patients have a mild MSMD phenotype. Two siblings identified with this defect both presented with recurrent and disseminated <em>Salmonella</em> infections. Other manifestations reported include recurrent herpes simplex virus (HSV) infections, recurrent respiratory syncytial virus (RSV) pneumonitis, and hepatosplenic mycobacterial disease.</p><p class="headingAnchor" id="H12958675"><span class="h2">Dominant negative LOF STAT1 deficiency</span><span class="headingEndMark"> — </span>Partial STAT1 deficiency with autosomal dominant (AD) inheritance (MIM #614892) due to heterozygous point pathogenic variants in the <em>STAT1</em> gene has been described in multiple kindreds [<a href="#rid56">56,57</a>]. These defects typically cause problems with phospho-STAT1 dimer formation or DNA binding, leading to impaired expression of IFN-gamma-directed STAT1-induced genes. However, this AD pathogenic variant interferes less with IFN-alpha-induced ISGF3 formation, thereby sparing IFN-alpha/beta-mediated antiviral activity. Patients with these pathogenic variants have more localized BCG or nontuberculous mycobacteria (NTM) infection in childhood with good responses to therapy. The clinical and cellular phenotypes of these patients are similar to those of patients with AR partial or AD IFNGR deficiency. (See <a class="local">'Autosomal recessive partial IFNGR1 or IFNGR2 deficiencies'</a> above.)</p><p class="headingAnchor" id="H224657537"><span class="h2">Autosomal dominant GOF STAT1 deficiency</span><span class="headingEndMark"> — </span>Gain-of-function (GOF) <em>STAT1</em> pathogenic variants (MIM #614162) are the most common variants in STAT1. This disease was initially described as causing chronic mucocutaneous candidiasis (CMCC), but the phenotype is now recognized as variable, with broad infection manifestations, autoimmunity, and vasculopathy. [<a href="#rid58">58</a>] Infections range from CMCC to NTM (typically more focal than in STAT1 deficiency), disseminated fungal infections, bacterial infections, and recurrent viral infections including herpes family infections but also severe viral infections, such as JC driven progressive multifocal encephalopathy (PML) [<a href="#rid59">59</a>]. Autoimmunity is common and ranges from isolated thyroid disease to extensive immune dysregulation similar to immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) [<a href="#rid59">59,60</a>].</p><p>The mucosal disease is likely driven by increased T cells with increased IFN-gamma/STAT1 signaling, but the variable phenotypes remain not well understood. Most cases can be managed with prevention and treatment of infections (often maintenance antifungal therapy and anti-HSV prophylaxis). Janus kinase inhibitor (JAKi or Jakinib) therapy are increasingly used in patients with autoimmune complications and CMCC [<a href="#rid61">61,62</a>], but its long-term efficacy is unknown. Initial outcomes with HCT were poor, but with HCT prior to development of significant disease and with improved control of IFN-gamma signaling prior to HCT, there have been more successes [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Signal transducer and activator of transcription (STAT1) dysfunction'</a> and  <a class="medical medical_review" href="/d/html/3924.html" rel="external">"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"</a>.)</p><p class="headingAnchor" id="H1016484"><span class="h1">IRF8 DEFICIENCY</span><span class="headingEndMark"> — </span>Interferon (IFN) regulatory factor 8 (IRF8; encoded on chromosome 16q24.1) is a transcription factor predominantly in mononuclear phagocytes that regulates myeloid cell function, granulocyte and macrophage differentiation, and dendritic cell development [<a href="#rid64">64-66</a>]. It is also critical for defense against intracellular pathogens, activating antimycobacterial defenses via production of interleukin (IL) 12 in response to IFN-gamma, among other cytokines. It is a key regulator for early response in myeloid cells, including phagosome maturation, antigen processing, and antigen presentation [<a href="#rid67">67</a>].</p><p>Autosomal recessive (AR) IRF8 deficiency (MIM #226990) due to homozygous K108E pathogenic variants led to a complete absence of circulating monocytes and dendritic cells along with myeloid hyperplasia [<a href="#rid68">68,69</a>]. One patient identified with this genotype presented in early infancy with disseminated Bacillus Calmette-Guérin (BCG) infection and oral candidiasis. Subsequent reports have also demonstrated viral susceptibility, as well as developmental delay with intracerebral calcifications [<a href="#rid70">70</a>]. This form of IRF8 deficiency likely needs early hematopoietic cell transplantation (HCT).</p><p>Autosomal dominant (AD) IRF8 deficiency (MIM #614893) due to heterozygous T80A pathogenic variants caused selective absence of circulating dendritic cells [<a href="#rid68">68</a>] found in association with disseminated BCG disease. This form of IRF8 deficiency responded well to antimicrobial therapy.</p><p class="headingAnchor" id="H3663155"><span class="h1">GATA2 DEFICIENCY (MonoMAC SYNDROME)</span><span class="headingEndMark"> — </span>GATA-binding protein 2 (GATA2; encoded on 3q21.3) is an early hematopoietic transcription factor that is required for myeloid and erythroid development. As such, there are no human cases of complete GATA2 deficiency. GATA2 deficiency is an autosomal dominant (AD) disorder by haploinsufficiency (eg, one allele is not enough). The main clinical manifestations include mycobacterial infections, viral infections, pulmonary alveolar proteinosis, myelodysplasia, and leukemia [<a href="#rid71">71-74</a>]. GATA2 deficiency has been called monocytopenia and MAC (MonoMAC); dendritic cell, monocyte, and B and natural killer (NK) lymphoid deficiency (DCML deficiency); Emberger syndrome; the syndrome of familial myelodysplasia and acute leukemia; and the syndrome of NK cell deficiency. (See  <a class="medical medical_review" href="/d/html/3949.html" rel="external">"NK cell deficiency syndromes: Clinical manifestations and diagnosis", section on 'Autosomal dominant GATA2 deficiency'</a>.)</p><p>Most commonly, AD GATA2 deficiency leads to the syndrome of monocytopenia and mycobacterial disease (MonoMAC; MIM #614172), which is characterized by late childhood or adult onset of disseminated nontuberculous mycobacterial (NTM) disease [<a href="#rid71">71-74</a>]. Complete blood count (CBC) with differential and lymphocyte subset analysis in these patients are remarkable for absolute circulating monocytopenia, NK cell cytopenia, and B cell lymphopenia. However, tissue macrophages and plasma cells are present, and immunoglobulin levels are normal to elevated, reflecting the fact that these patients start out life with normal complements of cells and then lose them over time but keep the plasma cells and macrophages derived from them.</p><p>Mycobacterial infections are common in late childhood or adulthood in patients with GATA2 deficiency [<a href="#rid71">71-74</a>]. Viral infections beginning in childhood include human papillomavirus, molluscum contagiosum, and herpes virus family including severe herpes simplex virus (HSV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) infections. Invasive fungal infections include histoplasmosis and aspergillosis. Lymphedema, deafness, and myelodysplasia are seen more often with null alleles (stop codons, frame shifts, or deletions) [<a href="#rid75">75</a>]. Myelodysplasia frequently develops over time, associated with cytogenetic abnormalities in the bone marrow (eg, trisomy 8 and monosomy 7). Other presentations of this syndrome include chronic neutropenia, aplastic anemia (AA), acute myelogenous leukemia, acute lymphocytic leukemia, and chronic myelomonocytic leukemia [<a href="#rid76">76-79</a>]. Bone marrow flow cytometry, morphology, and cytogenetics can help distinguish idiopathic AA from GATA2 deficiency [<a href="#rid78">78</a>]. Pulmonary alveolar proteinosis develops over time in approximately one-third of patients but may not have the typical "crazy paving" associated with anti-granulocyte macrophage (GM) colony-stimulating factor (CSF) autoantibodies [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial MDS/AML with mutated GATA2'</a>.)</p><p>Diagnosis is suspected based upon infections (persistent warts, mycobacterial infections), abnormal CBC with differential (leukopenia, monocytopenia), and /or family history of leukemia or myelodysplasia. Severe genital warts or cervical dysplasia should also prompt consideration of AD GATA2 deficiency. Sequencing of the <em>GATA2</em> gene leads to definitive diagnosis. However, intronic variants account for approximately 25 percent of cases, and they may not be detected on typical exome or panel sequencing platforms [<a href="#rid74">74</a>].</p><p>Hematopoietic cell transplantation (HCT) for GATA2 deficiency is highly successful and is the treatment of choice [<a href="#rid81">81,82</a>].</p><p class="headingAnchor" id="H1044560"><span class="h1">ISG15 DEFICIENCY</span><span class="headingEndMark"> — </span>Interferon (IFN) stimulated gene 15 (ISG15, encoded on chromosome 1p36.33) is a ubiquitin-like protein that becomes conjugated to many cellular proteins upon activation. It induces the production of IFN-gamma by lymphocytes, including natural killer (NK) cells [<a href="#rid83">83</a>].</p><p>Autosomal recessive (AR) ISG15 deficiency (MIM #616126) has been reported in three patients from two consanguineous families [<a href="#rid83">83</a>]. The phenotype is similar to interleukin (IL) 12 p40 and IL-12 receptor beta 1 (IL12RB1) deficiencies. The probands both presented with disseminated Bacillus Calmette-Guérin (BCG) infections with fistulizing ulcers and lymphadenopathies. In both patients, the infections resolved after prolonged antimycobacterial therapy. The brother of one of these patients, who also had ISG15 deficiency, had a milder infection with BCG. Three other unrelated patients with ISG15 deficiency presented with idiopathic basal ganglia calcification and seizures; these patients did not have significant infections or mycobacterial disease but did not receive BCG vaccination [<a href="#rid84">84</a>].</p><p>An increased susceptibility to viral infections was not observed in the six reported patients [<a href="#rid84">84</a>]. The uncontrolled IFN-alpha/beta amplification leads to autoinflammation and likely accounts for the basal ganglia calcifications, which were seen in patients regardless of mycobacterial infection.</p><p class="headingAnchor" id="H11422897"><span class="h1">NEMO DEFICIENCY</span><span class="headingEndMark"> — </span>Nuclear factor-kappa-B (NFkB) essential modulator (NEMO) is a member of a complex of proteins required to ubiquitinate the inhibitor of NFkB (IkB), thereby allowing activation of NFkB-induced genes. It is encoded by <em>IKBKG</em> on the X chromosome (Xq28) and associated with the syndrome of ectodermal dysplasia with immunodeficiency (ED-ID; MIM # 300291). It is closely related to the dominant form of IKB-alpha deficiency, caused by heterozygous pathogenic variants in <em>NFKBIA</em>, which also lead to ectodermal dysplasia and immunodeficiency. NEMO and IkB-alpha are both associated with disseminated mycobacterial infections in addition to bacterial and viral infections. Autoinflammatory disease may be present as well, such as colitis. (See  <a class="medical medical_review" href="/d/html/3951.html" rel="external">"Syndromic immunodeficiencies"</a>.)</p><p class="headingAnchor" id="H381300378"><span class="h1">MACROPHAGE GP91PHOX DEFICIENCY</span><span class="headingEndMark"> — </span>Pathogenic variants in the gene encoding gp91phox (<em>CYBB</em>) cause X-linked chronic granulomatous disease (CGD), which is due to an impaired phagocyte respiratory burst and predisposes to bacterial and fungal infections, including Bacillus Calmette-Guérin (BCG) and <em>M. tuberculosis</em>. (See  <a class="medical medical_review" href="/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a> and  <a class="medical medical_review" href="/d/html/3925.html" rel="external">"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>Specific pathogenic variants in the extracellular and transmembrane portions of <em>CYBB</em> lead to an unusual cellular phenotype in which neutrophil and monocyte respiratory burst function is normal (unlike in CGD), but the respiratory burst of differentiated macrophages is severely affected [<a href="#rid85">85</a>]. The seven affected patients from two kindreds in this report presented with BCG disease. The role of gp91phox in NADPH oxidase is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3925.html" rel="external">"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H2642222651"><span class="h1">TYK2 DEFICIENCY</span><span class="headingEndMark"> — </span>Tyrosine kinase 2 (Tyk2) is a member of the Janus kinase (JAK) family of kinases and is required for signal transduction from surface receptors to signal transducer and activator of transcription (STAT) molecules, making it a critical member of the JAK-STAT pathway. Tyk2 is involved in signaling for alpha and beta interferons (IFNs); interleukin (IL) 6, 10, and 13; granulocyte colony-stimulating factor (G-CSF); and IL-12 and -23. Autosomal recessive (AR) Tyk2 deficiency (MIM #611521) was initially described as a cause of a hyperimmunoglobulin E (hyper-IgE) syndrome with disseminated Bacillus Calmette-Guérin (BCG) [<a href="#rid86">86</a>]. Subsequent cases have demonstrated mycobacterial and viral susceptibility, mostly without IgE elevation. Tyk2 involvement in IL-12 and IL-23 signaling likely explains its role in mycobacterial susceptibility, including disseminated BCG, tuberculosis, and viral infections [<a href="#rid87">87</a>]. Common pathogenic variants in <em>TYK2</em> (found in 1 to 5 percent of Europeans) have been associated with increased susceptibility to tuberculosis [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H2888371075"><span class="h1">SPPL2A DEFICIENCY</span><span class="headingEndMark"> — </span>Signal peptide peptidase-like 2A (SPPL2A) is a transmembrane protease involved in the degradation of the human leukocyte antigen (HLA) invariant chain for antigen-presenting cells. Autosomal recessive (AR) loss-of-function (LOF) pathogenic variants were described in two unrelated families with Bacillus Calmette-Guérin (BCG) infections [<a href="#rid89">89</a>]. Without this degradation, the N-terminal fragment of the HLA invariant chain accumulates, leading to an impaired development of circulating dendritic cells and diminished interleukin (IL) 12 and interferon (IFN) gamma production and signaling, thus predisposing patients to BCG infections.</p><p class="headingAnchor" id="H1917207871"><span class="h1">ROR-GAMMA-T DEFICIENCY</span><span class="headingEndMark"> — </span>The retinoic acid-related orphan receptor member, <em>RORC,</em> encodes ROR-gamma-t, a transcription factor important in CD4 lymphoid development and differentiation to T helper cell type 17 (Th17) cells. Autosomal recessive (AR) loss-of-function (LOF) pathogenic variants were reported in three families in which patients had mucocutaneous candidiasis and disseminated Bacillus Calmette-Guérin (BCG) [<a href="#rid90">90</a>]. As expected from its role in Th17 development, Th17 cells were deficient. Less expected was the defective interferon (IFN) gamma response, predominantly of the gamma-delta T cells and the CD4+CCR6 and CXCR3+ alpha-beta T cells, to mycobacteria.</p><p class="headingAnchor" id="H1955053613"><span class="h1">JAK1 DEFICIENCY</span><span class="headingEndMark"> — </span>Both interferon (IFN) gamma and IFN-alpha/beta signal via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. IFN-gamma binds to its receptor, which leads to activation of JAK1 and JAK2, allowing phosphorylation of STAT1 and its downstream targets. IFN-alpha/beta binds to its receptors, leading to activation of JAK1 and tyrosine kinase (TYK) 2, followed by phosphorylation of STAT1 and STAT2, allowing activation of IFN-stimulated genes. Thus, disruption of JAK1 impacts both the IFN-gamma and IFN-alpha/beta pathways.</p><p>One patient was reported with homozygous missense <em>JAK1</em> mutations who had early-onset developmental delay and recurrent bacterial infections, viral infections (herpes zoster, warts), fungal infections, and disseminated nontuberculous mycobacteria (NTM) [<a href="#rid91">91</a>]. The patient then developed metastatic bladder cancer in early adulthood. Consistent with the partial JAK1 deficiency, diminished STAT phosphorylation was found. Presumably, full JAK1 deficiency would be lethal in utero or early in life.</p><p class="headingAnchor" id="H2686626650"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H2642016"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Host defense against Bacillus Calmette-Guérin (BCG), nontuberculous mycobacteria (NTM), as well as <em>Salmonella</em> and other intramacrophagic pathogens, including <em>Mycobacterium tuberculosis</em>, depends upon the interferon (IFN) gamma/ interleukin (IL) 12/signal transducer and activator of transcription (STAT) 1 pathway  (<a class="graphic graphic_figure graphicRef50107" href="/d/graphic/50107.html" rel="external">figure 1</a>). Genetic defects in this pathway result in mycobacterial and other infections  (<a class="graphic graphic_table graphicRef140002" href="/d/graphic/140002.html" rel="external">table 2</a>). It is important to consider that autoantibodies to IFN-gamma can fully mimic MSMD and are most commonly found in people of Southeast Asian origin. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/89801.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL12RB1 and IL-12p40 deficiencies – </strong>IL-12 receptor beta 1 (IL12RB1) deficiency is the most common cause of MSMD. IL12RB1 and IL-12p40 deficiency have variable presentations but frequently present as disseminated BCG or, in countries without BCG vaccination, with disseminated NTM or with disseminated intracellular bacterial infections such as salmonellosis. (See <a class="local">'IL12RB1 deficiency'</a> above and <a class="local">'IL-12 p40 deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IFNGR defects</strong> – IFN-gamma receptor (IFNGR) defects are one of the most commonly identified causes of MSMD. They can be recessive, which are typically severe and require hematopoietic cell transplantation (HCT), or dominant. Patients with IFNGR2 deficiency tend to develop severe disseminated mycobacterial disease in infancy or early childhood, requiring continuous antimycobacterial therapy and HCT. Autosomal dominant (AD) partial IFNGR1 deficiency usually presents later in childhood or in adolescence with severe localized (ie, multifocal osteomyelitis) or disseminated BCG or NTM infections, disseminated endemic mycoses, or salmonellosis. AD partial IFNGR2 deficiency and autosomal recessive (AR) partial IFNGR1 and IFNGR2 deficiencies are rare. (See <a class="local">'IFN-gamma receptor deficiencies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>STAT1 defects</strong> – Recessive complete loss of STAT1 is severe, with severe mycobacterial and viral infections and early mortality. Dominant negative (DN) pathogenic variants are milder, predispose to more localized NTM infections, and are medically manageable. Dominant gain-of-function (GOF) STAT1 pathogenic variants often present with mucocutaneous candidiasis and viral and bacterial infections but can also have NTM infections. (See <a class="local">'STAT1 defects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GATA2 deficiency</strong> – GATA-binding protein 2 (GATA2) deficiency leads to the syndrome of monocytopenia and mycobacterial disease (MonoMAC), which predisposes to late childhood or adult onset of disseminated NTM disease, viral infections, myelodysplasia and leukemia, and pulmonary alveolar proteinosis. (See <a class="local">'GATA2 deficiency (MonoMAC syndrome)'</a> above.)</p><p></p><p class="headingAnchor" id="H2894451044"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, and Gulbu Uzel, MD, who contributed as Section Editor and author, respectively, to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rosain J, Kong XF, Martinez-Barricarte R, et al. Mendelian susceptibility to mycobacterial disease: 2014-2018 update. Immunol Cell Biol 2019; 97:360.</a></li><li><a class="nounderline abstract_t">Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008; 122:1043.</a></li><li><a class="nounderline abstract_t">de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998; 280:1435.</a></li><li><a class="nounderline abstract_t">Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280:1432.</a></li><li><a class="nounderline abstract_t">Caragol I, Raspall M, Fieschi C, et al. Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor beta1 deficiency. Clin Infect Dis 2003; 37:302.</a></li><li><a class="nounderline abstract_t">Staretz-Haham O, Melamed R, Lifshitz M, et al. Interleukin-12 receptor beta1 deficiency presenting as recurrent Salmonella infection. Clin Infect Dis 2003; 37:137.</a></li><li><a class="nounderline abstract_t">Lichtenauer-Kaligis EG, de Boer T, Verreck FA, et al. Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency. Eur J Immunol 2003; 33:59.</a></li><li><a class="nounderline abstract_t">Fieschi C, Dupuis S, Catherinot E, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med 2003; 197:527.</a></li><li><a class="nounderline abstract_t">Haerynck F, Holland SM, Rosenzweig SD, et al. Disseminated Mycobacterium avium infection in a patient with a novel mutation in the interleukin-12 receptor-beta1 chain. J Pediatr 2008; 153:721.</a></li><li><a class="nounderline abstract_t">Gruenberg DA, Añover-Sombke S, Gern JE, et al. Atypical presentation of IL-12 receptor beta1 deficiency with pneumococcal sepsis and disseminated nontuberculous mycobacterial infection in a 19-month-old girl born to nonconsanguineous US residents. J Allergy Clin Immunol 2010; 125:264.</a></li><li><a class="nounderline abstract_t">de Beaucoudrey L, Samarina A, Bustamante J, et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010; 89:381.</a></li><li><a class="nounderline abstract_t">Altare F, Ensser A, Breiman A, et al. Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J Infect Dis 2001; 184:231.</a></li><li><a class="nounderline abstract_t">Ouederni M, Sanal O, Ikinciogullari A, et al. Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β1 deficiency. Clin Infect Dis 2014; 58:204.</a></li><li><a class="nounderline abstract_t">Martínez-Barricarte R, Markle JG, Ma CS, et al. Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol 2018; 3.</a></li><li><a class="nounderline abstract_t">Holland SM, Dorman SE, Kwon A, et al. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis 1998; 178:1095.</a></li><li><a class="nounderline abstract_t">Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941.</a></li><li><a class="nounderline abstract_t">Lamhamedi S, Jouanguy E, Altare F, et al. Interferon-gamma receptor deficiency: relationship between genotype, environment, and phenotype (Review). Int J Mol Med 1998; 1:415.</a></li><li><a class="nounderline abstract_t">Altare F, Jouanguy E, Lamhamedi-Cherradi S, et al. A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. Am J Hum Genet 1998; 62:723.</a></li><li><a class="nounderline abstract_t">Altare F, Jouanguy E, Lamhamedi S, et al. Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 1998; 10:413.</a></li><li><a class="nounderline abstract_t">Roesler J, Kofink B, Wendisch J, et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp Hematol 1999; 27:1368.</a></li><li><a class="nounderline abstract_t">Jouanguy E, Dupuis S, Pallier A, et al. In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma. J Clin Invest 2000; 105:1429.</a></li><li><a class="nounderline abstract_t">Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998; 101:2364.</a></li><li><a class="nounderline abstract_t">Cottle LE. Mendelian susceptibility to mycobacterial disease. Clin Genet 2011; 79:17.</a></li><li><a class="nounderline abstract_t">Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004; 364:2113.</a></li><li><a class="nounderline abstract_t">Dorman SE, Uzel G, Roesler J, et al. Viral infections in interferon-gamma receptor deficiency. J Pediatr 1999; 135:640.</a></li><li><a class="nounderline abstract_t">Casanova JL, Ochs H. Interferon-gamma receptor deficiency: An expanding clinical phenotype? J Pediatr 1999; 135:543.</a></li><li><a class="nounderline abstract_t">Fleisher TA, Dorman SE, Anderson JA, et al. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin Immunol 1999; 90:425.</a></li><li><a class="nounderline abstract_t">Bax HI, Freeman AF, Ding L, et al. Interferon alpha treatment of patients with impaired interferon gamma signaling. J Clin Immunol 2013; 33:991.</a></li><li><a class="nounderline abstract_t">Chantrain CF, Bruwier A, Brichard B, et al. Successful hematopoietic stem cell transplantation in a child with active disseminated Mycobacterium fortuitum infection and interferon-gamma receptor 1 deficiency. Bone Marrow Transplant 2006; 38:75.</a></li><li><a class="nounderline abstract_t">Roesler J, Horwitz ME, Picard C, et al. Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey. J Pediatr 2004; 145:806.</a></li><li><a class="nounderline abstract_t">Moilanen P, Korppi M, Hovi L, et al. Successful hematopoietic stem cell transplantation from an unrelated donor in a child with interferon gamma receptor deficiency. Pediatr Infect Dis J 2009; 28:658.</a></li><li><a class="nounderline abstract_t">Olbrich P, Martínez-Saavedra MT, Perez-Hurtado JM, et al. Diagnostic and therapeutic challenges in a child with complete interferon-γ receptor 1 deficiency. Pediatr Blood Cancer 2015; 62:2036.</a></li><li><a class="nounderline abstract_t">Olbrich P, Dimitrova D, Gennery A, et al. International survey and retrospective analysis of 29 patients with IFN-gamma-receptor deficiency. Bone Marrow Transplant 2021; 56(S1):100.</a></li><li><a class="nounderline abstract_t">Holland SM, Pierce VM, Shailam R, et al. Case 28-2017. A 13-Month-Old Girl with Pneumonia and a 33-Year-Old Woman with Hip Pain. N Engl J Med 2017; 377:1077.</a></li><li><a class="nounderline abstract_t">Zerbe CS, Holland SM. Disseminated histoplasmosis in persons with interferon-gamma receptor 1 deficiency. Clin Infect Dis 2005; 41:e38.</a></li><li><a class="nounderline abstract_t">Vinh DC, Masannat F, Dzioba RB, et al. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. Clin Infect Dis 2009; 49:e62.</a></li><li><a class="nounderline abstract_t">Edgar JD, Smyth AE, Pritchard J, et al. Interferon-gamma receptor deficiency mimicking Langerhans' cell histiocytosis. J Pediatr 2001; 139:600.</a></li><li><a class="nounderline abstract_t">Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999; 21:370.</a></li><li><a class="nounderline abstract_t">Yancoski J, Sadat MA, Aksentijevich N, et al. A novel internalization motif regulates human IFN-γ R1 endocytosis. J Leukoc Biol 2012; 92:301.</a></li><li><a class="nounderline abstract_t">Holland SM. Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection. Microbes Infect 2000; 2:1579.</a></li><li><a class="nounderline abstract_t">Holland SM. Immunotherapy of mycobacterial infections. Semin Respir Infect 2001; 16:47.</a></li><li><a class="nounderline abstract_t">Zerbe CS, Dimitrova D, Gea-Banacloche JJ, et al. Successful Matched Related Bone Marrow Transplantation in a Patient with Autosomal Dominant Interferon Gamma Receptor 1 Deficiency. J Clin Immunol 2020; 40:1045.</a></li><li><a class="nounderline abstract_t">Rosenzweig SD, Dorman SE, Uzel G, et al. A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol 2004; 173:4000.</a></li><li><a class="nounderline abstract_t">Kong XF, Vogt G, Itan Y, et al. Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease. Hum Mol Genet 2013; 22:769.</a></li><li><a class="nounderline abstract_t">Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. J Clin Invest 1997; 100:2658.</a></li><li><a class="nounderline abstract_t">Döffinger R, Jouanguy E, Dupuis S, et al. Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J Infect Dis 2000; 181:379.</a></li><li><a class="nounderline abstract_t">Sologuren I, Boisson-Dupuis S, Pestano J, et al. Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet 2011; 20:1509.</a></li><li><a class="nounderline abstract_t">Altare F, Lammas D, Revy P, et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection. J Clin Invest 1998; 102:2035.</a></li><li><a class="nounderline abstract_t">Picard C, Fieschi C, Altare F, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 2002; 70:336.</a></li><li><a class="nounderline abstract_t">Prando C, Samarina A, Bustamante J, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore) 2013; 92:109.</a></li><li><a class="nounderline abstract_t">Parvaneh N, Barlogis V, Alborzi A, et al. Visceral leishmaniasis in two patients with IL-12p40 and IL-12Rβ1 deficiencies. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003; 33:388.</a></li><li><a class="nounderline abstract_t">Chapgier A, Wynn RF, Jouanguy E, et al. Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol 2006; 176:5078.</a></li><li><a class="nounderline abstract_t">Chapgier A, Kong XF, Boisson-Dupuis S, et al. A partial form of recessive STAT1 deficiency in humans. J Clin Invest 2009; 119:1502.</a></li><li><a class="nounderline abstract_t">Averbuch D, Chapgier A, Boisson-Dupuis S, et al. The clinical spectrum of patients with deficiency of Signal Transducer and Activator of Transcription-1. Pediatr Infect Dis J 2011; 30:352.</a></li><li><a class="nounderline abstract_t">Dupuis S, Dargemont C, Fieschi C, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293:300.</a></li><li><a class="nounderline abstract_t">Chapgier A, Boisson-Dupuis S, Jouanguy E, et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet 2006; 2:e131.</a></li><li><a class="nounderline abstract_t">Depner M, Fuchs S, Raabe J, et al. The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1. J Clin Immunol 2016; 36:73.</a></li><li><a class="nounderline abstract_t">Toubiana J, Okada S, Hiller J, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 2016; 127:3154.</a></li><li><a class="nounderline abstract_t">van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365:54.</a></li><li><a class="nounderline abstract_t">Higgins E, Al Shehri T, McAleer MA, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 2015; 135:551.</a></li><li><a class="nounderline abstract_t">Forbes LR, Vogel TP, Cooper MA, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol 2018; 142:1665.</a></li><li><a class="nounderline abstract_t">Leiding JW, Okada S, Hagin D, et al. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol 2018; 141:704.</a></li><li><a class="nounderline abstract_t">Weisz A, Marx P, Sharf R, et al. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J Biol Chem 1992; 267:25589.</a></li><li><a class="nounderline abstract_t">Chiquet BT, Lidral AC, Stal S, et al. CRISPLD2: a novel NSCLP candidate gene. Hum Mol Genet 2007; 16:2241.</a></li><li><a class="nounderline abstract_t">Marquis JF, LaCourse R, Ryan L, et al. Disseminated and rapidly fatal tuberculosis in mice bearing a defective allele at IFN regulatory factor 8. J Immunol 2009; 182:3008.</a></li><li><a class="nounderline abstract_t">Marquis JF, Kapoustina O, Langlais D, et al. Interferon regulatory factor 8 regulates pathways for antigen presentation in myeloid cells and during tuberculosis. PLoS Genet 2011; 7:e1002097.</a></li><li><a class="nounderline abstract_t">Hambleton S, Salem S, Bustamante J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365:127.</a></li><li><a class="nounderline abstract_t">Salem S, Langlais D, Lefebvre F, et al. Functional characterization of the human dendritic cell immunodeficiency associated with the IRF8(K108E) mutation. Blood 2014; 124:1894.</a></li><li><a class="nounderline abstract_t">Bigley V, Maisuria S, Cytlak U, et al. Biallelic interferon regulatory factor 8 mutation: A complex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulation. J Allergy Clin Immunol 2018; 141:2234.</a></li><li><a class="nounderline abstract_t">Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115:1519.</a></li><li><a class="nounderline abstract_t">Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118:2653.</a></li><li><a class="nounderline abstract_t">Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011; 118:2656.</a></li><li><a class="nounderline abstract_t">Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. Blood 2013; 121:3830.</a></li><li><a class="nounderline abstract_t">Wlodarski MW, Collin M, Horwitz MS. GATA2 deficiency and related myeloid neoplasms. Semin Hematol 2017; 54:81.</a></li><li><a class="nounderline abstract_t">Kazenwadel J, Secker GA, Liu YJ, et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 2012; 119:1283.</a></li><li><a class="nounderline abstract_t">Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014; 123:809.</a></li><li><a class="nounderline abstract_t">Ganapathi KA, Townsley DM, Hsu AP, et al. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. Blood 2015; 125:56.</a></li><li><a class="nounderline abstract_t">Collin M, Dickinson R, Bigley V. Haematopoietic and immune defects associated with GATA2 mutation. Br J Haematol 2015; 169:173.</a></li><li><a class="nounderline abstract_t">Marciano BE, Olivier KN, Folio LR, et al. Pulmonary Manifestations of GATA2 Deficiency. Chest 2021; 160:1350.</a></li><li><a class="nounderline abstract_t">Cuellar-Rodriguez J, Gea-Banacloche J, Freeman AF, et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood 2011; 118:3715.</a></li><li><a class="nounderline abstract_t">Parta M, Shah NN, Baird K, et al. Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen. Biol Blood Marrow Transplant 2018; 24:1250.</a></li><li><a class="nounderline abstract_t">Bogunovic D, Byun M, Durfee LA, et al. Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science 2012; 337:1684.</a></li><li><a class="nounderline abstract_t">Zhang X, Bogunovic D, Payelle-Brogard B, et al. Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation. Nature 2015; 517:89.</a></li><li><a class="nounderline abstract_t">Bustamante J, Arias AA, Vogt G, et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol 2011; 12:213.</a></li><li><a class="nounderline abstract_t">Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25:745.</a></li><li><a class="nounderline abstract_t">Kreins AY, Ciancanelli MJ, Okada S, et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 2015; 212:1641.</a></li><li><a class="nounderline abstract_t">Boisson-Dupuis S, Ramirez-Alejo N, Li Z, et al. Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a common TYK2 missense variant. Sci Immunol 2018; 3.</a></li><li><a class="nounderline abstract_t">Kong XF, Martinez-Barricarte R, Kennedy J, et al. Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency. Nat Immunol 2018; 19:973.</a></li><li><a class="nounderline abstract_t">Okada S, Markle JG, Deenick EK, et al. IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 2015; 349:606.</a></li><li><a class="nounderline abstract_t">Eletto D, Burns SO, Angulo I, et al. Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection. Nat Commun 2016; 7:13992.</a></li></ol></div><div id="topicVersionRevision">Topic 3958 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30264912" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mendelian susceptibility to mycobacterial disease: 2014-2018 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19084105" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603733" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603732" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12856223" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor beta1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12830418" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Interleukin-12 receptor beta1 deficiency presenting as recurrent Salmonella infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594833" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591909" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18940359" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Disseminated Mycobacterium avium infection in a patient with a novel mutation in the interleukin-12 receptor-beta1 chain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910038" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Atypical presentation of IL-12 receptor beta1 deficiency with pneumococcal sepsis and disseminated nontuberculous mycobacterial infection in a 19-month-old girl born to nonconsanguineous US residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21057261" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11424023" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24186907" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical features of Candidiasis in patients with inherited interleukin 12 receptorβ1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30578351" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Human IFN-γimmunity to mycobacteria is governed by both IL-12 and IL-23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9806040" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960473" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9852244" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interferon-gamma receptor deficiency: relationship between genotype, environment, and phenotype (Review).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9497247" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9722917" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mendelian susceptibility to mycobacterial infection in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10480427" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811850" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9616207" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20718793" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mendelian susceptibility to mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589309" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10547254" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Viral infections in interferon-gamma receptor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10547240" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Interferon-gamma receptor deficiency: An expanding clinical phenotype?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10075873" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Detection of intracellular phosphorylated STAT-1 by flow cytometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23512243" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Interferon alpha treatment of patients with impaired interferon gamma signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16715106" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Successful hematopoietic stem cell transplantation in a child with active disseminated Mycobacterium fortuitum infection and interferon-gamma receptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15580206" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451859" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Successful hematopoietic stem cell transplantation from an unrelated donor in a child with interferon gamma receptor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26173802" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnostic and therapeutic challenges in a child with complete interferon-γreceptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : International survey and retrospective analysis of 29 patients with IFN-gamma-receptor deficiency</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28902581" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Case 28-2017. A 13-Month-Old Girl with Pneumonia and a 33-Year-Old Woman with Hip Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16028145" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Disseminated histoplasmosis in persons with interferon-gamma receptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681704" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598613" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Interferon-gamma receptor deficiency mimicking Langerhans' cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192386" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595141" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A novel internalization motif regulates human IFN-γR1 endocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113377" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11309712" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immunotherapy of mycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32696284" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Successful Matched Related Bone Marrow Transplantation in a Patient with Autosomal Dominant Interferon Gamma Receptor 1 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356149" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23161749" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389728" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10608793" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266457" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854038" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11753820" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429356" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27873456" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Visceral leishmaniasis in two patients with IL-12p40 and IL-12Rβ1 deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12590259" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585605" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436109" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A partial form of recessive STAT1 deficiency in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20962705" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The clinical spectrum of patients with deficiency of Signal Transducer and Activator of Transcription-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11452125" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16934001" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26604104" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27114460" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21714643" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25662309" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30092289" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28601685" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1460054" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17616516" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : CRISPLD2: a novel NSCLP candidate gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19234196" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Disseminated and rapidly fatal tuberculosis in mice bearing a defective allele at IFN regulatory factor 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21731497" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Interferon regulatory factor 8 regulates pathways for antigen presentation in myeloid cells and during tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21524210" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : IRF8 mutations and human dendritic-cell immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25122610" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Functional characterization of the human dendritic cell immunodeficiency associated with the IRF8(K108E) mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29128673" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Biallelic interferon regulatory factor 8 mutation: A complex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20040766" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670465" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21765025" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23502222" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28637621" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : GATA2 deficiency and related myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147895" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24227816" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359990" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25707267" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Haematopoietic and immune defects associated with GATA2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34089740" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pulmonary Manifestations of GATA2 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21816832" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29412158" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22859821" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mycobacterial disease and impaired IFN-γimmunity in humans with inherited ISG15 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25307056" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Human intracellular ISG15 prevents interferon-α/βover-amplification and auto-inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21278736" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088085" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304966" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30578352" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Tuberculosis and impaired IL-23-dependent IFN-γimmunity in humans homozygous for a common TYK2 missense variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30127434" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26160376" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28008925" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
